Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03725059
Title Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

invasive ductal carcinoma

Therapies

Cyclophosphamide + Doxorubicin + Paclitaxel + Pembrolizumab

Cyclophosphamide + Epirubicin + Paclitaxel

Pembrolizumab

Cyclophosphamide + Doxorubicin + Paclitaxel

Cyclophosphamide + Epirubicin + Paclitaxel + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA | CAN


No variant requirements are available.